focus -WSS

focus

author：hotspot 2025-09-28 01:34:58 - browse：9

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： What to make of Biden’s latest efforts on cancer research

WSS

Covid hospitalizations on the rise, Humana says

Long Covid needs a new name — and a new frame

Snackable artificial intelligence, expert AI, and the pharma industry

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

PEPFAR is under serious threat — and so is global health

IRA could hurt research into orphan drugs for rare diseases

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Medical leaders decry Supreme Court decision on affirmative action

What to make of Biden’s latest efforts on cancer research

Activists slam private health insurers over coverage restrictions

The (many) problems with a new study criticizing cancer screening

How one medical school became remarkably diverse

Advances in CAR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Generate Biomedicines machine learning biotech raises $273M

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

'Make People Better': The CRISPR babies story you probably don't know

focus

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

How generative AI is inspiring dreams of a health data revolution

Long Covid needs a new name — and a new frame

FDA panel endorses Alnylam’s heart drug — after picking it apart

Advances in CAR

Acelyrin, a rare IPO success, stumbles in its first big test

focus

leisure time

hotspot

Wikipedia